The outbreak caused by Enterococcus faecium and E. faecalis with Van B phenotype in patients with haematological malignancies;Zakażenia fenotypem Van B Enterococcus faecium i E. faecalis u chorych z niedoborem immunologicznym w przebiegu chorób nowotworowych układu krwiotwórczego

Medycyna Doswiadczalna i Mikrobiologia

Volumn 55, Issue 1, 2003, Pages 11-24

  Kȩdzierska, Jolanta ^a   Wȩgrzyn, Joanna ^b   Skotnicki, Aleksander B ^b   Skop, Agata ^b   Pawliszyn, Wacław ^a  

^a Szpital Uniwersyteckiego   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; GLYCOPEPTIDE; IMIPENEM; LINEZOLID; METRONIDAZOLE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TETRACYCLINE DERIVATIVE; VANCOMYCIN; BACTERIAL PROTEIN; VANB PROTEIN, ENTEROCOCCUS;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DRUG ACTIVITY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EPIDEMIOLOGICAL DATA; FEMALE; GENUS; HEMATOLOGIC MALIGNANCY; HOSPITALIZATION; HUMAN; IN VITRO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PATHOGENESIS; PHENOTYPE; PROMOTER REGION; RISK FACTOR; AGED; ANTIBIOTIC RESISTANCE; BLOOD DISEASE; COMORBIDITY; EPIDEMIC; GENETICS; IMMUNE DEFICIENCY; LENGTH OF STAY; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; POLAND; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; BACTERIAL PROTEINS; COMORBIDITY; DISEASE OUTBREAKS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; LENGTH OF STAY; MALE; MIDDLE AGED; PHENOTYPE; POLAND; VANCOMYCIN RESISTANCE;

EID: 0642283083     PISSN: 00258601     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 1993; 37: 1563-71.
2. Aslangul E, Baptista M, Fantin F i inni. Selection of glycopeptide-resistant mutants of vanB-type Enterococcus faecalis BM4281 in vitro and in experimental endocarditis. J Infect Dis 1997; 175: 598-605.
3. Baptista M, Rodrigues P, Depardieu P. i inni. Single-cell analysis of glycopeptide resistance gene expression in teicoplanin-resistant mutants of VanB Enterococcus f->aecalis. Mol Microbiol 1999; 32: 17-28.
4. Betlejewska K, Hryniewicz W. Nowe antybiotyki w leczeniu zakażeń wywołanych przez wielooporne szczepy ziarenkowców Gram-dodatnich. Nowa Med. 1999; 9: 35-39.
5. Bradley SJ, Wilson ALT, Allen MC i inni. The control hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 1999; 43: 261-66.
6. Dever LL, China C, Eng RHK i inni. Vancomycin-resistant Enterococcus faecium in a Veterans Affairs Medical Centre: association with antibiotic usage. Am J Infect Control 1998; 26: 40-46.
7. Hayden MK, Trenholme J, Schultz E, Sahm DF. In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate. J Infect Dis 1993; 167: 1224-27.
8. Hryniewicz W, Szczypa K, Bronk A i inni. First report of vancomycin-resistant Enterococcus faecium isolated in Poland. Clin Microbiol Infect 1999; 5: 503-5.
9. Ieven M, Vercauteren P, Descheemaeker F i inni. Comparison of direct plating and broth enrichment culture for the detection of intestinal colonization by the glycopeptide-resistant Enterococci among hospitalized patients. J Clin Microbiol 1999; 37: 1436-40.
10. th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 26-29, 1999.
11. Kawalec M, Gniadkowski M, Kȩdzierska J i inni. Selection of a teicoplanin-resistant Enterococcus faecium mutant during outbreak caused by vancomycin-resistant Enterococci with VanB phenotype. J Clin Microbiol 2001; 39: 3258-67.
12. Kawalec M, Gniadkowski M, Zaleska T i inni. Outbreak of vancomycin-resistant Enterococcus faecium of the phenotype VanB in a hospital in Warsaw, Poland: probable transmission of the resistance determinants into a endemic vancomycin-susceptible strain. J Clin Microbiol 2001; 39: 1781-87.
13. Kawalec M, Zarȩba T. Patogeneza zakażeń enterokokowych. Nowa Med. 1997; 4: 26-30.
14. Linden PK, Pasculle AW, McDevitt D, Kramer DJ. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. J Antimicrob Chemother 1997; 39: 145-151.
15. Łȩkowska-Kochaniak AE. Enterokoki (paciorkowce kałowe) - probiotyki czy patogeny? Post Mikrobiol 2000; 4: 341-61.
16. Murray BE. Vancomycin-resistant enterococcal infection. N Eng J Med. 2000; 342: 710-21.
17. Szczypa K, Hryniewicz W. Linezolid - nowe możliwości terapeutyczne. Nowa Klinika 2001; 8: 929-32.
18. Uttley AHC, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1989; 33: 1588-91.
19. Vancomycin resistant enterococci in hospitals in the United Kingdom (ed.): CDR Wkly 1995; 5: 281-84.
20. Van der Auwera P, Pensart N, Korten V i inni. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis 1996; 173: 1129-36.
21. Wells Cl, Juni BA, Cameron SB i inni. Stool carriage, clinical isolation and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis 1995; 21: 45-50.
22. Wieczyńska J, Kamińska W, Dzierzanowska D. Enterokoki - patogeny XXI wieku. Post Mikrobiol 2001; 40: 257-78.